Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis.
about
Tools for monitoring remission in rheumatoid arthritis: any will do, let's just pick one and start measuringComparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analyPatient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literatureToward characterization and definition of fibromyalgia severity.Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDARapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized contPre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid arthritis patientsAnakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis.Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial)ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?Patient-provider interactions in the management of chronic pain: current findings within the context of shared medical decision making.Issues in the design of new clinical trials for rheumatoid arthritis therapeutics.Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial.Randomized controlled trial design in rheumatoid arthritis: the past decade.Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis.Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis.Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).Correlates and predictors of disability in vulnerable US Hispanics with rheumatoid arthritis.Relative responsiveness of physician/assessor-derived and patient-derived core set measures in rheumatoid arthritis trials.Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.Is Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis Still a More Severe Disease Than Anti-Citrullinated Protein Antibody-Negative Rheumatoid Arthritis? A Longitudinal Cohort Study in Rheumatoid Arthritis Patients Diagnosed From 2000
P2860
Q21195253-598EDCC7-1947-4A18-835E-BBDA6B0E4E97Q27694496-9E239535-6F9A-4848-9229-4B8AA72A7F4BQ28071844-1558C2F2-E588-4AAE-8673-098773D25174Q33551013-6BA61275-0FAE-458D-A015-B54112090105Q34269994-45E5284F-09E1-46B8-BD9C-082BD4F972A1Q34413310-F161881D-04A2-41FD-A6CA-479FDB189B62Q34688901-C1F3489D-5115-416D-9C39-4E31E8CFF1A1Q35842626-E4EC5FD7-0DA1-433B-A1F9-D34A7507C061Q35954580-89FCBAB9-558C-4D28-A192-1FEBD8C1FA90Q36366162-9CA181D4-7DC6-4146-B72D-AEB62DAA06EFQ36374666-90E22BBC-AC5D-4934-A891-D599B97E2B14Q36715835-495077A6-3843-4306-A5C4-733171471700Q37335856-BE13DCA2-88B8-46B0-8F01-E0BE1005FFCDQ37374959-296590B6-1D92-4D92-87C6-8E953AACDC68Q37397646-E8A94066-3445-4B0A-878B-C9642A5BDF6AQ37728501-56C914AE-4BBB-47EB-AEBB-3E8630CD693AQ38372369-7CC500D0-ACB3-4EEF-9594-B43E0251C2EDQ38529234-48D1210F-7388-40BF-AD17-F97E6BAB648FQ39230189-3DEAEA1A-1F79-4C2E-9B89-4867C0612401Q39631082-1F01BFD4-0CB1-441E-AEF2-41AC39950C62Q42562298-9BBB8F34-8EF7-456E-BF8A-FE1030A1C079Q46514972-E2BA5376-1077-4971-8A19-358C94FE0CD0Q47191075-8BACA22E-E07C-488A-A30C-2E0BF7229898Q47265715-812A3767-AF39-4326-BF20-8EB7A1B7E5F2
P2860
Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Patient-reported outcomes bett ...... rials in rheumatoid arthritis.
@en
Patient-reported outcomes bett ...... rials in rheumatoid arthritis.
@nl
type
label
Patient-reported outcomes bett ...... rials in rheumatoid arthritis.
@en
Patient-reported outcomes bett ...... rials in rheumatoid arthritis.
@nl
prefLabel
Patient-reported outcomes bett ...... rials in rheumatoid arthritis.
@en
Patient-reported outcomes bett ...... rials in rheumatoid arthritis.
@nl
P2093
P2860
P356
P1433
P1476
Patient-reported outcomes bett ...... rials in rheumatoid arthritis.
@en
P2093
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEH140
P577
2004-03-23T00:00:00Z